Lista de obras -

A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology Faculty ⬇️

artículo científico publicado el 1 de noviembre de 2010

A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment

scientific article published on 22 June 2015

A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change.

artículo científico publicado en 2011

ATM gene single nucleotide polymorphisms predict regimen-related gastrointestinal toxicity in patients allografted after reduced conditioning

artículo científico publicado en 2015

Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma: Data from National Czech Registry

artículo científico publicado en 2006

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile

artículo científico publicado en 2011

Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia

scientific article published on 01 December 2011

Comparison of reduced conditionings combining fludarabine with melphalan or 3-day busulfan in patients allografted for myeloid neoplasms

scientific article published on 11 October 2014

Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications

artículo científico publicado en 2013

Detailed study of imatinib metabolization using high-resolution mass spectrometry

artículo científico publicado en 2015

Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy

artículo científico publicado en 2014

Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.

artículo científico publicado en 2013

First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter

scientific article published on 24 April 2019

Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma.

artículo científico publicado en 2010

Granulocyte transfusions collected after steroid priming for severe infections during neutropenia: A single center experience

artículo científico publicado en 2018

Has the time come for induction and maintenance imatinib therapy in chronic myeloid leukemia?

artículo científico publicado en 2008

High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma

artículo científico publicado en 2012

High serum carbohydrate antigen-125 (CA-125) level predicts poor outcome in patients with follicular lymphoma independently of the FLIPI score

artículo científico publicado en 2012

Identification of e6a2 BCR-ABL fusion in a Philadelphia-positive CML with marked basophilia: implications for treatment strategy.

artículo científico publicado en 2011

Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher pla

artículo científico publicado en 2010

Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results.

artículo científico publicado en 2009

Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting

artículo científico publicado en 2012

Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial

artículo científico publicado en 2006

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.

artículo científico publicado en 2018

Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells ⬇️

artículo científico publicado el 12 de enero de 2011

Interferon-alpha in chronic myeloid leukemia revisited: a long-term retrospective study in Central and Northern Moravia.

artículo científico publicado en 2012

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

artículo científico publicado en 2016

Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing

scientific article published on 01 June 2006

Isotope dilution direct injection mass spectrometry method for determination of four tyrosine kinase inhibitors in human plasma.

artículo científico publicado en 2012

Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation.

artículo científico publicado en 2011

Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation

artículo científico publicado en 2009

Metabolite Profiling of the Plasma and Leukocytes of Chronic Myeloid Leukemia Patients

artículo científico publicado en 2016

Novel sulphur-containing imatinib metabolites found by untargeted LC-HRMS analysis.

artículo científico publicado en 2017

Operational cures after interferon-alpha in patients with chronic myeloid leukemia in Central and Northern Moravia

artículo científico publicado en 2011

Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia

artículo científico publicado en 2010

Possible impact of MADCAM1 gene single nucleotide polymorphisms to the outcome of allogeneic hematopoietic stem cell transplantation

artículo científico publicado en 2009

Precursor T-lymphoblastic lymphoma as a secondary malignancy in a young patient after successful treatment of acute promyelocytic leukemia

artículo científico publicado en 2009

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

artículo científico publicado en 2019

Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.

artículo científico publicado en 2009

Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma

artículo científico publicado en 2013

Rituximab does not adversely affect the stem cell mobilization and engraftment after high-dose therapy and autologous transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission

artículo científico publicado en 2009

Saliva as a diagnostic medium

artículo científico publicado en 2009

Salivary neutrophils level as an indicator of bone marrow engraftment

artículo científico publicado en 2009

Second Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

artículo científico publicado en 2018

Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT

artículo científico publicado en 2020

Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.

artículo científico publicado en 2014

Sources and pathways of spread of vancomycin-resistant enterococci in hemato-oncological patients

artículo científico publicado en 2006

Spontaneous splenic rupture in a patient with acute promyelocytic leukaemia during induction chemotherapy.

artículo científico publicado en 2013

Successful childbirth in a patient with chronic myelogenous leukemia treated with imatinib mesylate during early pregnancy.

artículo científico publicado en 2008

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

scientific article published on 29 June 2020

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

artículo científico publicado en 2024

Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration

artículo científico publicado en 2003

Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000--a report from the population-based CAMELIA Registry

artículo científico publicado en 2011

Ultrafast Online SPE-MS/MS Method for Quantification of 3 Tyrosine Kinase Inhibitors in Human Plasma.

artículo científico publicado en 2016

[Targeted treatment of chronic myeloid leukemia in the elderly patients]

artículo científico publicado en 2015

Lista de obras de

A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology Faculty ⬇️

A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment

A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change.

ATM gene single nucleotide polymorphisms predict regimen-related gastrointestinal toxicity in patients allografted after reduced conditioning

Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma: Data from National Czech Registry

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile

Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia

Comparison of reduced conditionings combining fludarabine with melphalan or 3-day busulfan in patients allografted for myeloid neoplasms

Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications

Detailed study of imatinib metabolization using high-resolution mass spectrometry

Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy

Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.

First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter

Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma.

Granulocyte transfusions collected after steroid priming for severe infections during neutropenia: A single center experience

Has the time come for induction and maintenance imatinib therapy in chronic myeloid leukemia?

High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma

High serum carbohydrate antigen-125 (CA-125) level predicts poor outcome in patients with follicular lymphoma independently of the FLIPI score

Identification of e6a2 BCR-ABL fusion in a Philadelphia-positive CML with marked basophilia: implications for treatment strategy.

Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher pla

Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results.

Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting

Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.

Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells ⬇️

Interferon-alpha in chronic myeloid leukemia revisited: a long-term retrospective study in Central and Northern Moravia.

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing

Isotope dilution direct injection mass spectrometry method for determination of four tyrosine kinase inhibitors in human plasma.

Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation.

Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation

Metabolite Profiling of the Plasma and Leukocytes of Chronic Myeloid Leukemia Patients

Novel sulphur-containing imatinib metabolites found by untargeted LC-HRMS analysis.

Operational cures after interferon-alpha in patients with chronic myeloid leukemia in Central and Northern Moravia

Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia

Possible impact of MADCAM1 gene single nucleotide polymorphisms to the outcome of allogeneic hematopoietic stem cell transplantation

Precursor T-lymphoblastic lymphoma as a secondary malignancy in a young patient after successful treatment of acute promyelocytic leukemia

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.

Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma

Rituximab does not adversely affect the stem cell mobilization and engraftment after high-dose therapy and autologous transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission

Saliva as a diagnostic medium

Salivary neutrophils level as an indicator of bone marrow engraftment

Second Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT

Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.

Sources and pathways of spread of vancomycin-resistant enterococci in hemato-oncological patients

Spontaneous splenic rupture in a patient with acute promyelocytic leukaemia during induction chemotherapy.

Successful childbirth in a patient with chronic myelogenous leukemia treated with imatinib mesylate during early pregnancy.

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration

Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000--a report from the population-based CAMELIA Registry

Ultrafast Online SPE-MS/MS Method for Quantification of 3 Tyrosine Kinase Inhibitors in Human Plasma.

[Targeted treatment of chronic myeloid leukemia in the elderly patients]